Prevention and treatment of hypergastrinemia

Details Prevention and treatment of hypergastrinemia Prevention and treatment of hypergastrinemia

A - Human Necessities

61

K

A61K 39/385 (2006.01) A61K 38/22 (2006.01) A61K 47/48 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C07K 14/595 (2006.01) C07K 16/26 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2328501

Serum-associated hypergastrinemia is treated by administration of gastrin active or passive immunization. An anti-gastrin immunogenic composition comprising a gastrin G17 or G34 peptide fragment which is amino acid spacer- linked to an immunogenic carrier, is administered so as to effectively neutralize the circulating gastrin hormone, and moreover, inhibit autocrine activity by progastrin such as Gly-extended G17, and amidated G17, in patients with pernicious anemia. Moreover, the method includes administration of a therapeutically effective amount of anti-G17 or anti-G34 antibodies which may be in humanized form. Finally, the method provides ameliorating treatment of hypergastrinemic effects of proton pump inhibitors or H2 histamine receptor blocking agents or antagonists, in addition to treatment of hypergastrinemia caused by diseases such as pernicious anemia.

L'invention se rapporte à un traitement de l'hypergastrinémie liée à un taux sérique de gastrine particulier, consistant à effectuer une immunisation active ou passive dirigée contre la sécrétion de gastrine. Pour ce faire, on administre aux patients atteints d'anémie de Biermer une composition immunogène anti-gastrine comportant un fragment peptidique G34 ou G17 de gastrine qui est lié par un bras écarteur aminoacide à un porteur immunogène, afin de neutraliser efficacement la gastrine circulante et d'inhiber, en outre, l'activité autocrine de la progastrine du type G17 à extension Gly, et G17 amidé. L'invention se rapporte également à l'administration d'une quantité thérapeutiquement efficace d'anticorps anti-G17 ou anti-G34 qui peuvent se présenter sous forme humanisée. Finalement, l'invention se rapporte à un traitement permettant d'atténuer les effets hypergastrinémiques des inhibiteurs de la pompe à protons ou des antagonistes ou agents bloquants du récepteur d'histamine H¿2?, ainsi qu'à un traitement de l'hypergastrinémie provoquée par des maladies telles que l'anémie de Biermer.

Affiliated with

Also associated with

Rating

Prevention and treatment of hypergastrinemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prevention and treatment of hypergastrinemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of hypergastrinemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2022715